Page 4 - Vercise Genus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Boston Scientific Announces Results For First Quarter 2021 News provided by Share this article Share this article MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an operational 1 basis and 5.9 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income available to common stockholders of $327 million or $0.23 per share (EPS), compared to GAAP net income of $...

Henry Ford first in the U.S. to offer FDA-approved DBS system to treat Parkinson's disease The Parkinson's Disease and Movement Disorder Center at Henry Ford Health System was the first in the United States to offer a new FDA-approved device to help treat the symptoms of Parkinson's disease. Neurosurgeon Jason Schwalb, M.D. surgically implanted the Vercise Genus™ Deep Brain Stimulation (DBS) System, which stimulates a targeted region of the brain through - implanted leads that are placed in the brain. The leads are powered by a device called an implantable pulse generator, which sits under ...

 E-Mail IMAGE: Jason Schwalb, M.D., just before surgically implanting the first Vercise Genus™ Deep Brain Stimulation (DBS) System in the United States. view more  Credit: Henry Ford Health System DETROIT (Feb. 18, 2021) - The Parkinson's Disease and Movement Disorder Center at Henry Ford Health System was the first in the United States to offer a new FDA-approved device to help treat the symptoms of Parkinson's disease. Neurosurgeon Jason Schwalb, M.D. surgically implanted the Vercise Genus™ Deep Brain Stimulation (DBS) System, which stimulates a targeted region of the brain th...

Boston Scientific Announces Results For Fourth Quarter And Full Year 2020 News provided by Share this article Share this article MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on an operational 1 basis and (8.0) percent on an organic 2 basis, all compared to the prior year period. Included within organic results is a negative 370 basis point impact associated with the conversion of U.S. WATCHMAN™ cu...

Operator Good morning, and welcome to the Boston Scientific Fourth Quarter 2020 Financial Results Conference Call. [Operator Instructions] I would now like to turn the conference over to Susan Lisa, Vice President, Investor Relations. Please go ahead. Susie Lisa -- Vice President, Investor Relations Thank you, Andrew. Good morning, everyone, and thanks for joining us. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer and Dan Brennan, Executive Vice President and Chief Financial Officer. We issued a press release earlier this morning announcing our Q4 2020 results...